CellaVision AB (publ) (CEVI)
AI Signal
HOLD
Sentiment
7/10
Risk
3/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis – $4.99
Sentiment is mostly positive after strong results and product updates, focusing on Bone Marrow, the dividend, and Americas growth. Some caution remains around FX and elevated expectations into Q1.
Exchange
Nasdaq Stockholm
Type
Tech
Sector
Medtech diagnostics (digital hematology)
Market Cap
$389M
Why HOLD ?
- **Hold**: Profitable company with **low debt** and a strong niche position.
- Upside from new applications exists, but **expectations are high** into Q1 and 2026 milestones.
- Waiting for Q1 confirmation and early Bone Marrow revenue signals reduces timing risk.
- Hold; consider increasing 10–15% after a strong Q1 and clear Bone Marrow traction.
- Bull case: - **Q1 report (24 Apr 2026)** could confirm continued strong organic growth, especially in the Americas.
Recent News
- Strong Q4 2025 with ~12% organic growth and ~33% EBITDA margin. The board proposed a SEK 2.75 per share dividend, and the company is progressing the 2026 rollout/commercialization of the Bone Marrow application.
15 Aug 2026 —
Bone Marrow: visible revenue impact
Want to read the full AI analysis?
Buy express analysis of CellaVision AB (publ) – ready in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- PDF + saved to your account
- Ready in 5–15 min (email when ready)
Secure payment via Stripe – 7-day money-back guarantee
Advanced AI analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.